France Pregabalin Market Outlook

pregabalin, a (gabapentin analogue) small molecule drug targeting central neuropathic pain, seizures, and anxiety disorder, is increasingly finding preference among physicians upon competition from other drugs. in france, the demand of pregabalin is much desired by physicians for its offered comprehensive results. with recent developments in the french healthcare system, the market of pregabalin is pitched upon an all-time high. various factors are encouraging the french healthcare providers and physicians across the country to prescribe pregabalin over other drugs. factors such as improved patient compliance and low drug interactions, to name a few, are boosting the presence of pregabalin in france. moreover, generics such as gabaz launched by recently introduced french players are amplifying the perceived availability and choice of pregabalin. apart from this, the growing french population with increasing need for cost-effective solutions in healthcare is spurring the demand of pregabalin in france. according to a survey, a common french man prefers pregabalin over any other drugs for the same. also, pregabalin (under trade names lyrica and gabaz max) has been enlisted in the current essential drugs list of the national medicines agency of france, a testament of the social acceptance of pregabalin. in 2018, the sales of pregabalin from the french market stood at a noteworthy amount. a 2019 survey indicated commendable sales outcome for pregabalin in france in 2019 as well. this suggests that pregabalin will hold leadership in the french market for the years to come. in the long-term span of 2018 to 2032, with the launch of generics, increasing number of prescriptions for pregabalin, and rising awareness of its potential, well-placed strategies and awareness programs, the market for pregabalin in france is likely to be supported with a significant demand for the same. despite global competition from countries like india, china, and the us, pregabalin is likely to maintain its position in the french market. new approaches for pharmacosurveillance of pregabalin in france, as well as new methods of treatment, expanded insurance coverage, and nationwide campaigns for the drug may further escalate the pregabalin market in france in the future. thus, it is clear that the market outlook of pregabalin in france is set to be a bright one for the near future.